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Abstract
Although a number of studies on the phenotypic changes that occur after T-cell activation have already been published, the specific immunophenotypic
features of T-lymphocytes and the frequency at which TCR-variable region (TCR-V) restricted T-cell expansions occur “in vivo” during acute viral
infection still remains to be established. We report on the immunophenotype and TCR-V repertoire of peripheral blood T-cells from 28 patients with acute
infectious mononucleosis. Immunophenotypic studies were performed by flow cytometry using direct immunofluorescence techniques and stain-and-
then-lyse sample preparation protocols with three- and four-colour combinations of monoclonal antibodies directed against a large panel of T- and NK-cell
associated markers, activation- and adhesion-related molecules and TCR-V, -V and -V families. Nearly all patients (27/28) showed a massive
expansion of CD8/TCR T cells, the majority (90%) of which displayed an immunophenotype compatible with T-cell activation: CD2high,
CD7low, CD11ahigh, CD38high, HLA-DRhigh, CD28/low, CD45ROhigh, CD45RA/low, CD11b/low, CD11c/low, CD16, CD56,
CD57, CD62L, CD94, CD158a, CD161, NKB1. Additionally, the levels of both CD3 and CD5 were slightly decreased compared to those found
in normal individuals. Late-activation antigens, such as CD57, were found in small proportions of CD8/TCR T-cells. Increased numbers of
CD4/TCR T-cells, TCR T-cells and NK-cells were also noticed in 17, 16 and 13 of the 28 cases studied, respectively. Evidence for
activation of CD4/TCR and TCR T-cells relied on changes similar to those described for CD8/TCR although less pronounced,
except for higher levels of both CD5 and CD28 in the absence of reactivity for CD11c on CD4/TCR T-cells and higher levels of CD161
and CD94 on TCR T-cells. Small expansions of one or more TCR-V families accounting for 12 7% of either the CD8/TCR or the
CD4/TCR T-cell compartment were found in 12 of 14 patients studied, whereas the distribution of the TCR-V and -V repertoires tested
in 2 of the individuals with expanded TCR T-cells was similar to that observed in control individuals. The results presented here provide
evidence for an extensive T-cell activation during acute viral infection and establish the immunophenotype patterns associated with this condition.
© 2003 Elsevier Science (USA). All rights reserved.
Keywords: Infectious mononucleosis; T-cells; Flow cytometry; Immunophenotype; TCR-V repertoire
Introduction
The term acute infectious mononucleosis (AIM) is usu-
ally used to designate a syndrome that associates with acute
viral infection [1]. Besides Epstein–Barr virus (EBV), other
herpes viruses may also be involved [2–5] and primary
infection with human retroviruses may occasionally exhibit
a mononucleosis-like presentation [6,7]. In most occasions,
AIM develops and evolves as a benign self-limited disease;
however, some patients develop serious complications, oc-
casionally with a fatal outcome. Fever, lymphadenitis, phar-
yngitis and jaundice are frequent clinical findings. In con-
trast, arthritis, gastroenteritis, pneumonitis, mediastinitis,
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encephalitis, orchitis, haemophagocytic syndrome, splenic
infarct and rupture are much less frequent complications of
the disease [8–18]. Laboratory findings include lymphocy-
tosis with circulating atypical lymphocytes, liver cytolysis
and colestasis. Severe cytopenias may be noted in some
patients [19–21].
Previous studies suggest that B-cells are the primary
target of EBV infection and that infected B-cells could act
as a virus reservoir, although T-cells may be infected as well
[22–24]. Additionally, evidence exists that patients with
AIM show an increased proliferation of reactive activated
CD8 T-lymphocytes [25–27], some of which are specific
for viral antigens [28]. Increased levels of T-cell derived
cytokines and other soluble factors may have a specific role
in both the immune response and the clinical manifestations
associated with AIM [29–31].
The relationship between EBV infection and the devel-
opment of clonal lymphoproliferative disorders (LPD) has
been extensively investigated in immunosuppressed pa-
tients, especially in transplant recipients [32,33]. Accord-
ingly, it is now generally accepted that after viral infection
these individuals may develop clonal expansions of lym-
phocytes that may end up in the so-called post-transplant
LPD. Infection with EBV was also documented in both T-
and NK-cell lymphomas as well as in other haematological
and non-haematological malignancies [34,35] and there is
evidence for a direct relationship between chronic EBV
infection and lymphomagenesis [36,37]. Previous studies
based on both immunophenotypic analysis of the T-cell
receptor (TCR) V repertoire and assessment of molecular
clonality suggest the possibility of occurrence of both oli-
goclonal and monoclonal T-cell expansions during AIM in
otherwise normal individuals, although data available in the
literature are controverse [38–44].
A number of studies have focused on the immunophe-
notypic changes occurring during T-cell activation [45–56].
These reports show that both early and late T-cell activation
stages can be identified though the analysis of specific
phenotypic changes involving up- and down-regulation of
different cell surface proteins. Accordingly, some antigens,
such as CD69, are transiently up-regulated just after T-cell
activation [47] whereas other markers have been recognized
to appear at relatively early stages and persist thereafter;
these include up-regulation of HLA-DR, CD38, CD2 and
CD11a and a decreased expression of the CD28 T-cell
costimulatory molecule [45–57]. Finally, expression of
other antigens, such as CD57, typically occur in a later
phase of the T-cell response [58–60]. In spite of these
well-established changes occurring after T-cell activation, a
comprehensive study describing the specific immunopheno-
typic features of T- lymphocytes during acute viral infection
is still lacking in the literature; in addition, the frequency at
which TCR-V restricted T-cell expansions occur in AIM
still remains to be established.
A detailed characterization of the T-cell phenotypes ob-
served in AIM will provide the basis for the understanding
of the biological changes (up- or down-regulation of cell
receptors, adhesion molecules and other functional mem-
brane proteins) occurring “in vivo” in conditions of “ex-
treme” cellular activation. From the clinical point of view, it
also has an immediate application in cases in which differ-
ential diagnosis with lymphoma is pertinent, especially for
patients presenting with lymphadenopathies and/or organo-
megalies as well as for those individuals in whom serolog-
ical screening for common viral diseases is not conclusive.
In the present paper we explore in detail the immuno-
phenotypic characteristics of peripheral blood (PB) T-cells,
including the analysis of their TCR-V repertoire, in a
group of 28 adult patients with well-documented AIM.
Material and methods
Patients
A total of 28 patients (16 males and 12 females with a
mean age of 30 years; range 11 to 58 years) diagnosed as
suffering from AIM were included in this study. None of
these patients had previous evidence for an underlying im-
munodeficiency and none of them received previous immu-
nosuppressive drugs. The possibility of ingestion of drugs
that have been associated with an AIM-like syndrome was
also excluded. Two patients had been previously splenec-
tomised, one of them because of autoimmune haemolytic
anaemia and the other due to a traumatic splenic rupture.
Fever, malaise, lymphadenopathy, splenomegaly, hepato-
megaly and pharingitis were found in 88%, 84%, 54%,
24%, 28% and 28% of the cases, respectively. Purpura and
other muco-cutaneous haemorrhage occurred in 2 cases,
both presenting with severe thrombocytopenia. Other less
frequent clinical findings included ictericiae in 3 patients,
skin rash in 2 cases, gastroenteritis, otitis, vertiginous syn-
drome, disturbed consciousness with unknown origin and
autoimmune haemolytic anaemia, pneumonitis, uveitis and
encephalitis observed in 1 patient each. All but 1 patient had
an acute self-limited disease, with clinical resolution in 9 
8 weeks (range: 2 to 23 weeks). Twenty-five patients re-
covered spontaneously without need for specific therapy
while in 2 patients treatment for severe thrombocytopenia
and haemorrhage, consisting of high dose intravenous im-
munoglobulins and steroids, was needed and given. The
remaining patient, who had been previously splenectomised
for autoimmune haemolytic anaemia, evolved into a chronic
disease with ophthalmic, pulmonary and neurological com-
plications. This patient was treated with steroids, intrave-
nous immunoglobulins and acyclovir without success and
dyed with active CMV infection 1 year later.
Six normal healthy individuals (blood donors) were used
as controls (3 males and 3 females with a mean age of 45
years, ranging from 37 to 51 years).
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Samples
In all cases EDTA-K3 anti-coagulated PB samples were
obtained at diagnosis for immunophenotypic analysis of
circulating T- and NK-cells as well as other laboratory
studies which are listed below.
Flow cytometry immunophenotypic studies
Immunophenotypic analysis of surface antigen expres-
sion on PB lymphocytes was performed in all cases using
direct immunofluorescence techniques and a stain-and-then-
lyse sample preparation protocol. The monoclonal antibod-
ies (MoAb) used are shown in Table 1. Erythrocyte lysis
and cell fixation were performed using either FACS lysing
solution (Becton–Dickinson BioSciences, BD, San Jose´,
CA, USA)—for lymphocyte immunophenotyping—or Q-
Prep reagents (Beckman Coulter, Miami, FL, USA)—for
the analysis of the TCR-V, TCR-V and TCR-V reper-
toires.
In all cases the following three-colour combinations of
MoAb conjugated with fluorescein isothiocyanate (FITC),
phycoerythrin (PE) and peridin chlorophyll protein (PerCP)
were initially used in order to quantify and characterize the
major PB lymphocyte sub-populations (FITC/PE/PerCP):
CD19/CD2/CD45, CD3/CD16CD56/CD45, TCR/
TCR/CD3, CD4/CD8/CD3 and CD8/HLA-Dr/CD3.
CD8/TCR and CD4/TCR T-cells were fur-
ther characterized in 15 and 9 cases, respectively, using
three- or four-colour stainings that combined allophyco-
cyanin (APC) conjugated anti-CD8 and/or PerCP-conju-
gated anti-CD4 with the following pairs of MoAb (FITC/
PE): CD2/CD7, CD7/CD5, CD62L/CD28, CD16/CD56,
CD57/CD11c, CD38/CD11b, CD45RA/CD45RO, CD122/
CD25, CD11a/HLA-DR, CD94/CD8, CD16/NKB1 and
CD158a/CD161.
In addition, the TCR-V repertoire was evaluated in 14
of these patients by flow cytometry using triple-stainings
with anti-CD4-PerCP and anti-CD8-FITC (or PE) combined
with a panel of MoAb specific for 23 different TCR-V
families (FITC or PE) (Table 1). This panel of MoAb
identified a mean of 60  4% of CD4/TCR and 46 
6% of CD8/TCR T-cells in the PB of age-matched
normal healthy individuals.
Expression of p26/bcl2 was specifically explored on
CD8/TCR T-cells using the Fix & Perm reagent kit
(An Der Grub Bioresearch GmbH, Vienna, Austria) and
strictly following the recommendations of the manufacturer.
In three of the patients who showed increased numbers
of TCR T-cells, these cells were specifically studied by
Table 1
Specificities, clones and sources of the monoclonal antibodies used in the present study
Specificity Clone Conjugate Sourcea Specificity Clone Conjugate Sourcea Specificity Clone Conjugate Sourcea
CD2 SFCI3Pt2H9 FITC; PE BC CD62L SK11 FITC BD TCR-V8.1/.2 C2156C5.2 FITC IOT
CD3 UCHT1; SK7 FITC; PerCP IOT;
BD
CD94 HP-3D9 FITC PH TCR-V11.1 C21 FITC IOT
CD4 SK3 FITC, PerCP
or APC
BD CD122 MIK-b FITC CLB TCR-V12.2 VER2.32.1 FITC IOT
CD5 L17F12 PE BD CD158a HP-3E4 FITC BD TCR-V13.1 JU74.3 FITC IOT
CD7 CLB-3A1/1,7F3;
3A1E-12H7
FITC; PE CLB;
BC
CD161 DX12 PE BD TCR-V13.6 IMMV222 FITC IOT
CD8 SK1 PE; APC BD Bcl2/p26 124 FITC DK TCR-V14.1 CAS1.1.3 FITC IOT
CD11a CLB-LFA-1/2,
TB133
FITC CLB HLA-DR L243 PE BD TCR-V16.1 TAMAYA1.2 FITC IOT
CD11b D12 PE BD NKB1 DX9 PE BD TCR-V17.1 E17.5F3.15.13 FITC IOT
CD11c S-HCL-3 PE BD TCR- T10B9,1A-31 FITC PH TCR-V18.1 BA62.6 PE IOT
CD16 3G8 FITC; PE BC;
IOT
TCR-/ 11F2; B1 PE; APC BD; PH TCR-V20.1 ELL1.4 FITC IOT
CD19 89B FITC BC TCR-V1 BL37.2 FITC IOT TCR-V21.3 IG125 FITC IOT
CD25 2A3 PE BD TCR-
V2.1
MPB2D5 FITC IOT; BioD TCR-V22.1 IMMV546 FITC IOT
CD28 L293 PE BD TCR-
V3.1
CH92; 8F10 FITC IOT; END TCR-V23.1 AF23 PE IOT
CD38 LD38; HB7 FITC; PE CYT;
BD
TCR-
V5.1
IMMV157 FITC IOT TCR-V1 TCR2730 FITC END
CD45 2D1 PerCP BD TCR-
V5.2
36213 FITC IOT TCR-V2 P91464 FITC BIO
CD45RA L48 FITC BD TCR-
V5.3
3D11 PE IOT TCR-V3 P91564 FITC BIO
CD45RO UCHL-1 PE BD TCR-
V6.1
CRI304.3 FITC IOT TCR-V4 TCR2722 FITC END
CD56 NCAM16.2;
N901/NKH1
PE BD;
IOT
TCR-
V6.7
T145 FITC END TCR-V9 TCR2720 FITC END
CD57 HNK-1 FITC BD TCR-
V7.1
ZOE FITC IOT
a BC, Beckman Coulter, Miami, FL, USA; IOT, Immunotech, Marseille, France; BD, Becton–Dickinson, San Jose´, CA, USA; CLB, Amsterdam, The
Netherlands; DK, Dako A/S, Glostrup, Denmark; CYT, Cytognos, Salamanca, Spain; PH, PharMingen, San Diego, CA, USA; BioD, Biodesign International,
Kennebunk, ME, USA; END, Endogen, Woburn, MA, USA.
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using combinations of MoAb similar to those described
above for TCR T-cells except that anti-TCR-APC
was used instead of anti-CD4 and anti-CD8. In addition, in
2 of these patients both the TCR-V and TCR-V reper-
toires were assessed using a panel of MoAb specific for the
TCR-V and TCR-V chains (Table 1).
In all cases data acquisition was carried out using either
a two-laser FACScalibur flow cytometer (Becton–Dickin-
son)—for lymphocyte immunophenotyping—or an EPICS-
XL-MCL flow cytometer (Beckman/Coulter)—for analysis
of p26/bcl2 and the TCR-V repertoire; data analysis was
performed using the Paint-A-Gate (Becton–Dickinson) and
the XL2 (Beckman/ Coulter) software programs, respec-
tively. For each marker, antigen expression was evaluated
as percentage of positive cells, its mean fluorescence inten-
sity (MFI) and coefficient of variation (CV).
Other laboratory tests
Sera from all patients were tested for the presence of
antibodies against the following viruses and parasites: anti-
EBV viral capside antigen IgG and IgM, anti-cytomegalo-
virus (CMV) immunoglobulins, anti-herpes simplex virus
IgG and IgM, anti-herpes zoster virus IgG and IgM, anti-
rubella virus IgG and IgM, anti-hepatitis A, B and C (HCV)
viruses, anti-human immunodeficiency viruses (HIV) type 1
and 2, anti-human T cell leukaemia/lymphoma viruses type
I and II and anti-Toxoplasma gondii IgG and IgM.
In 22/28 cases the infectious agent was identified by
serological studies and corresponded to EBV in 11 cases,
CMV in 9 cases (from whom one was associated to T.
gondii and another to HCV infection), HCV in 2 cases (one
of which associated to CMV infection) and recent HIV in 1
case. In the remaining 6 patients the serological screening
gave negative results although both the clinical and other
laboratory features at diagnosis and the clinical outcome
were consistent with the diagnosis of AIM. One of these
cases was persistently positive for the CMV antigen without
serological evidence for acute CMV infection or reactiva-
tion of CMV infection.
Other laboratory parameters evaluated in all cases here
studied included a full haematological cell count, a mor-
phological evaluation of blood smears and a routine bio-
chemical survey including liver enzymes, serum creatinine
and lactic dehydrogenase (data not shown). Further bio-
chemical, radiological, immunological, microbiological and
histological studies were performed whenever necessary to
confirm the diagnosis.
Statistical analysis
For all variables under study, median, mean, standard
deviation, minimum and maximum were calculated. To
establish the statistical significance of the differences ob-
served between AIM patients and normal individuals, the
Mann–Whitney U and the Student t tests were used.
Results
Blood cell counts
The mean PB cell counts are summarized in Table 2. As
may be seen, most of the patients (25 of 28) presented with
lymphocytosis (3.5  109/L) that was higher than 10 
109/L in 9 individuals. Neutropenia was observed in 5
Table 2
Blood cell counts observed at diagnosis in patients with AIM (n  28)
Patients with AIM Controls,
normal rangeMean  standard deviation (range) % Cases with abnormal values
Decreased Increased
WBC ( 109/L) 12.4  5.9 (5.1–27.6) 0 50 4.0–10.0
Lymphocytes ( 109/L) 8.2  4.9 (2.1–21.7) 0 89 1.5–3.5
Neutrophils ( 109/L) 3.1  1.5 (0.6–6.9) 18 0 2.0–7.5
Haemoglobin (g/dl) 12.8  2.2 (7.9–16.8) 32 0 12.0–17.0
Platelets ( 109/L) 205  100 (10–417) 32 4 150–400
T-cells ( 106/L) 6963  4030 (1384–16964) 0 96 1100–1700
T-cells (%) 85  7% (67–94%) 0 89 67–76
NK-cells ( 106/L) 636  724 (94–3519) 21 57 200–400
NK-cells (%) 8  5% (2–20%) 75 0 10–20
B-cells ( 106/L) 260  211 (50–955) 50 18 200–400
B-cells (%) 4  3% (1–12%) 93 0 10–20
TCR/CD4 T-cells ( 106/L) 1290  599 (570–2815) 11 61 700–1100
TCR/CD4 T-cells (%) 18  7% (9–37%) 100 0 38–46
TCR/CD8 T-cells ( 106/L) 5354  3433 (620–13471) 0 96 500–900
TCR/CD8 T-cells (%) 63  12% (30–81%) 0 96 31–40
TCR T-cells ( 106/L) 431  795 (32–3594) 11 46 50–200
TCR T-cells (%) 6  8% (1–32%) 61 11 3–10
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individuals, being severe (1.0  109/L) in 2 of these
cases. Platelet counts 150  109/L were found in 9 cases,
of which 2—both of which were CMV—had severe
thrombocytopenia (10  109/L) whereas haemoglobin
levels 12 g/dl were noticed in 9 individuals.
As also shown in Table 2 increased absolute numbers of
T- (1700 106/L), NK- (400 106/L) and B-(400
106/L) cells were a relatively common finding in AIM: 96%,
57% and 18% of the patients, respectively. An abnormally
low CD4/CD8 ratio was observed in 27/28 patients (mean
of 0.32 0.23, ranging from 0.11 to 1.23) being mainly due
to the existence of increased absolute numbers (900 
106/L) of CD8/TCR T-cells. CD4/TCR T-cell
counts were either increased (1100  106/L; n  17),
normal (n  8) or decreased (700  106/L; n  3, one
case being HIV). Increased numbers of TCR T-cells
(200  106/L) were observed in 13 cases. In 3 of these
cases—2 of which were EBV—there was a marked
TCR T-cell lymphocytosis, ranging from 916 to 3594
106/L.
Immunophenotypic characteristics of PB lymphocytes
Peripheral blood T-cells from patients with AIM were
phenotypically different from normal PB T-cells, concern-
ing both the percentage of cells expressing each of the
antigens analysed, their levels of expression (low versus
high) and the pattern (homogeneous versus heterogeneous)
of antigen expression. All patients had evidence of exten-
sive T-cell activation affecting mainly the CD8/TCR
T-cell compartment. These phenotypic changes were ac-
companied by a markedly decreased expression of p26/bcl2
on CD8/TCR T-cells towards negativity (mean of 89
 9% bcl2 cells; range 67 to 98%). CD4/TCR and
TCR T-cells from AIM patients also showed evidence
of cell activation and phenotypic changes were similar to
those observed on CD8/TCR cells, but less pro-
nounced. Bellow we describe in more detail the specific
phenotypic features observed for these T-cell subsets.
TCR T-cells
Data concerning the immunophenotypic features of
CD8 and CD4/TCR T-cells from patients with AIM
and normal individuals are presented in Tables 2 and 3 and
exemplified in Fig. 1. No statistically significant differences
were observed in the percentage of CD8 and CD4/
TCR T-cells that stained positively for CD2, CD5 and
CD7, with more than 95% of cells expressing these markers
in both patients and control individuals. In spite of this,
most pan-T-cell markers showed activation-dependent mod-
ulation, consisting of either up- or down-regulation of their
levels on the cell surface (Table 3). Accordingly, in AIM
patients expression of CD7 was decreased on both CD8 (P
 0.001) and CD4/TCR T-cells (P 0.025). Regard-
ing CD2, a tendency towards an increased expression was
observed on both TCR T-cell subsets, although differ-
ences did not reach statistical significance (P  0.05). As a
consequence, in patients with AIM CD2high/CD7low T-
cells accounted for a significantly higher proportions of both
Table 3
Modulation of antigen expression on peripheral blood CD8/TCR, CD4/TCR and TCR T-cell subsets in AIM patients
CD2 CD3 CD5 CD7 CD11a CD28 CD38 CD45RA CD45RO HLA-DR
CD8/TCRa
AIM 312  103 141 35 838 302 745 353 596 91 120 42 137 68 26 29 524 241 1334 634
(n  15) 282 141 817 632 608 114 130 19 423 1338
Controls 259  49 197 32 1033 153 2041 712 368 84 242 82 79 19 188 52 574 337 227 42
(n  6) 266 196 1034 2115 358 231 74 166 511 246
CD4/TCRb
AIM 293  80 297 88 1670 350 1107 421 385 155 276 119 126 56 124 45 771 301 953 431
(n  10) 262 261 1657 1180 350 243 136 116 673 932
Controls 229  32 433 39 1735 156 2163 837 223 54 413 206 34 10 155 138 788 593 410 144
(n  6) 219 434 1740 2302 203 421 32 94 793 389
TCRc
AIM 283  42 588 77 599 360 886 336 503 97 153 54 109 62 76 42 479 104 791 656
(n  3) 275 547 447 736 500 150 101 52 428 761
Controls 250  33 503 69 658 235 1678 823 348 111 417 119 42 16 230 140 392 235 93 23
(n  5) 265 475 538 1404 388 421 42 206 388 96
Note. Results are presented as the mean  one standard deviation and median (bold) of the mean fluorescence intensity (MFI) of positive cells, expressed
as arbitrary relative linear units scaled from 0 to 10,000. No differences were observed for the MFI of CD4 on CD4/TCR T-cells from patients with
AIM and controls (3821  792 versus 3606  541 and 95  39 versus 97  39, respectively).
a AIM versus controls: CD2: P  0.05; CD3: P  0.014; CD5: P  0.02; CD7: P  0.001; CD11a: P  0.002; CD28: P  0.003; CD38: P  0.043;
CD45RA: P  0.001; CD45RO: P  0.05; HLA-DR: P  0.001.
b AIM versus controls: CD2: P  0.05; CD3: P  0.028; CD5: P  0.05; CD7: P  0.025; CD11a: P  0.003; CD28: P  0.05; CD38: P  0.005;
CD45RA: P  0.05; CD45RO: P  0.05; HLA-DR: P  0.007.
c AIM versus controls: CD2: P  0.05; CD3: P  0.05; CD5: P  0.05; CD7: P  0.05; CD11a: P  0.053; CD28: P  0.025; CD38: P  0.053;
CD45RA: P  0.053; CD45RO: P  0.05; HLA-DR: P  0.025.
5M. Lima et al. / Blood Cells, Molecules, and Diseases 30 (2003) 1–12
Fig. 1. Representative dot plots illustrating the main phenotypic features of CD4 (red dots) and CD8 (black dots) TCR PB lymphocytes in normal
individuals (A) and in patients with AIM (B).
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CD8 (93  6% versus 59  14%; P  0.001) and CD4
(69 13% versus 50 19%; P 0.045) TCR T-cells.
Additionally, patients with AIM also showed decreased
CD3 expression on both CD8 (P  0.014) and CD4/
TCR T-cells (P  0.028), together with down-modu-
lation of CD28, this latter phenomenon being statistically
significant only for CD8/TCR T-cells (P  0.003). In
addition, the overall expression of CD28 on CD8/
TCR T-cells from AIM patients was more heteroge-
neous (mean CV of 186.7  70.2) than in controls (mean
CV of 102.0  13.0) (P  0.001). Similar results were
obtained for CD4/TCR T-cells, although differences
were less pronounced (mean CV of 90.5  44.7 and 52.1 
5.4, respectively; P  0.015). There were also differences
between CD8 and CD4/TCR T-cell subsets concern-
ing the expression of CD5 consistent with reduction on the
intensity of expression of this molecule on CD8 (P 
0.02) but not on CD4/TCR T-cells (P  0.05). No
significant differences were observed between AIM patients
and controls as regards the expression of CD4 and CD8
antigens on TCR T-cells.
Regarding the expression of adhesion molecules,
changes observed consisted mainly on the expression of
higher levels of CD11a on both CD8 (P  0.002) and
CD4/TCR T-cells (P  0.003) from AIM patients
compared to controls (Table 3). In normal PB, expression of
CD11a on T-cells showed a bimodal distribution, with two
distinct CD11a T-cell populations—CD11alow and
CD11ahigh—with CD11ahigh T-cells being more frequent
among the CD8 than the CD4/TCR PB T-cells. AIM
patients showed increased percentages of CD11ahigh T-
cells within both the CD8 (94  7% versus 55  8%; P
 0.001) and the CD4 (56  17% versus 33  14%; P 
0.013) TCR T-cell populations. With respect to the
expression of other adhesion molecules, CD8/TCR
T-cells but not CD4/TCR T-cells from AIM patients
showed a dim and heterogeneous expression of CD11c in
the vast majority of cases (80%), resulting in an overall
increase (P  0.002) in the percentage of CD8/CD11c
cells among these patients (Table 4); in cases that stained
positively for CD11c, this marker was expressed in a mean
fraction of 58  12% of CD8/TCR T-cells. In con-
trast, reactivity for CD11b was highly variable, this marker
being dimly expressed on CD8 and on CD4/TCR in
33% and 22% of the cases, respectively. This variability of
expression of CD11b explains why there were no statisti-
cally significant differences concerning the mean fraction of
CD11b cells between patients and controls when CD11b
and CD11b cases were considered all together (Table 4).
Up-regulation of adhesion molecules was accompanied by
down-regulation of the CD62L homing receptor, resulting
in a marked decrease on the percentage of CD8/CD62L
(P  0.002) and of CD4/CD62L TCR T-cells (P 
0.02) (Table 4).
Also probably reflecting the existence of an extensive
T-cell activation, there was an over-expression of CD38 in
both TCR T-cell populations from AIM patients, with a
marked increase on both the percentage of CD38 cells (P
 0.001 and P  0.007 for CD4 and CD8 T-cells,
respectively) and the intensity of expression of CD38 (P 
0.043 and P  0.005, respectively) (Tables 3 and 4). A
similar behaviour to that of CD38 was found for the
HLA-DR antigen, concerning both the fraction of HLA-
DR cells (P  0.001 for both CD8 and CD4/TCR
T-cells) and its intensity of expression (P  0.001 and P 
0.007, respectively) (see also Tables 3 and 4). Up-regulation
of CD11a, CD38 and HLA-DR was associated with both an
increase in the percentage of CD8/CD45RO cells (P 
0.001) and a decrease in the percentage of CD8/
CD45RA cells (P 0.005) (Table 4). In 75% of the cases,
CD8 T-cells expressed CD45ROhigh in the absence of a
clear reactivity for CD45RA, whereas in the remaining 25%
CD8 T-cells expressed lower levels of CD45RO (P 
0.001) and stained dimly for CD45RA. For that reason,
expression of CD45RA was markedly decreased (P 
0.001), whereas the overall intensity of expression of
CD45RO did not differ significantly from that observed in
controls (Table 3). Modulation of CD45RA/CD45RO ex-
pression on CD4 T-cells was much more subtle than that
observed on CD8 T-cells and consisted mainly on a de-
crease on the percentage of CD4/CD45RO/CD45RA
T-cells in patients with AIM (9  3% versus 18  9%)
together with a correspondent increase on the proportion of
CD4/CD45RO/CD45RA T-cells (P 0.045), no major
differences being detected regarding either the overall per-
centage of total CD4/CD45RA and CD4/CD45RO
TCR T-cells, or the overall intensity of CD45RA and
CD45RO expression (Tables 3 and 4). Regarding the CD25
antigen no statistically significant differences were observed
neither on the CD8 nor on the CD4 TCR T-cell
compartments (data not shown).
In most AIM cases only a few proportion of CD8 and
CD4/TCR T-cells were CD56 and/or CD57 (Table
4). It should be noted that the percentage of CD8/CD57
and/or CD4/CD57 T-cells exceeded 20% in only 3
cases—who also had the highest percentage of CD8/
CD56 and CD4/CD56 T-cells—all of which exhibited
increased proportions of large granular lymphocytes in the
PB smear. Two of these cases corresponded to patients who
had been previously splenectomised, the highest values be-
ing observed in the patient who became chronically infected
with CMV. Other NK-cell associated markers and killer
receptors (CD16, CD94, CD158a, CD161, NKBI) were
either negative or expressed in relatively small proportions
of both CD8 and CD4/TCR T-cells at values similar
to or even lower than those observed in controls (see also
Table 4).
TCR T-cells
The main immunophenotypic features of TCR T-
cells from patients with AIM and normal individuals are
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Table 4
Immunophenotypic characteristics of peripheral blood CD8/TCR, CD4/TCR and TCR T-cells in AIM patients
CD2high
CD7low
CD11ahigh CD11b CD11c CD16 CD28 CD38 CD45RA CD45RO CD45RA
CD45RO
CD56 CD57 CD62L CD94 CD158a CD161 HLADR NKB1
CD8/TCRa
AIM 93  6 94  7 16  24 47  28 1  1 49  24 92  7 26  25 92  5 19  24 5  5 12  16 10  14 0  0 1  1 10  5 91  10 1  1
(n  15) 94 97 4 54 1 42 94 12 92 6 3 7 5 0 1 10 95 1
Controls 59  14 55  8 16  6 6  5 6  8 68  7 4  2 68  16 53  9 25  3 18  11 33  5 51  10 15  9 5  8 13  7 17  8 3  4
(n  6) 63 53 16 4 0 66 3 75 51 27 14 32 50 11 1 10 13 1
CD4/TCRb
AIM 69  13 56  17 9  10 4  5 0  0 92  13 51  16 26  13 83  11 9  3 3  4 11  12 10  10 0* 0  0 26  9 52  16 0  0
(n  10) 70 53 6 3 0 97 47 23 87 9 1 4 8 0 25 55 0
Controls 50  19 33  14 1  1 0  0 0  0 98  3 27  9 41  16 78  13 18  9 1  1 3  2 74  12 0  0 0  0 26  9 7  2 0  0
(n  6) 42 34 0 0 0 99 26 47 83 16 1 2 78 0 0 27 7 0
TCRc
AIM N.D 96  3 22  14 33  15 1  1 84  10 92  7 20  12 92  11 8  5 18  7 4  2 44* 85  1 1  1 73  13 89  12 1  1
(n  3) 98 28 32 0 85 93 24 98 10 19 4 85 1 78 94 1
Controls N.D. 53  18 51  16 35  14 16  15 49  16 4  4 77  20 65  15 42  17 37  11 44  16 46  13 37  13 10  12 56  14 52  12 5  5
(n  5) 61 61 31 17 42 3 88 75 40 35 45 46 38 2 56 49 3
Note. Results are expressed as the mean percentage of positive cells from the indicated T-cell subset  one standard deviation and median (bold). *Only one case was tested. n.d., not determined.
a AIM versus controls: CD2high/CD7low: P  0.001; CD11ahigh: P  0.001; CD11b: P  0.05; CD11c: P  0.002; CD16: P  0.05; ; CD28: P  0.05; CD38: P  0.001; CD45RA: P 
0.005; CD45RO: P  0.001; CD45RA/CD45RO: P  0.05; CD56: P  0.004; CD57: P  0.001; CD62L: P  0.002; CD94: P  0.015; CD158a: P  0.05; CD161: P  0.05; HLA-DR:
P  0.001; NKB1: P  0.05. No significant differences were observed between AIM patients and controls as regards the overall percentage of CD2 (99  0 versus 99  1), CD5 (99  1 versus 94
 5), and CD7 (96  5 versus 98  2) cells.
b AIM versus controls: CD2high/CD7low: P  0.045; CD11ahigh: P  0.013; CD11b: P  0.05; CD11c: P  0.019; CD16: P  0.05; CD28: P  0.05; CD38: P  0.007; CD45RA: P 
0.05; CD45RO: P  0.05; CD45RA/CD45RO: P  0.045; CD56: P  0.05; CD57: P  0.05; CD62L: P  0.02; CD158a: P  0.05; CD161: P  0.05; HLA-DR: P  0.001; NKB1: P
 0.05. No significant differences were observed between AIM patients and controls as regards the overall percentage of CD2 (99  0 versus 99  0), CD5 (99  0 versus 99  0), and CD7 (86 
14 versus 94  2) cells.
c AIM versus controls: CD11ahigh: P  0.025; CD11b: P  0.05; CD11c: P  0.05; CD16: P  0.05; CD28: P  0.025; CD38: P  0.025; CD45RA: P  0.025; CD45RO: P  0.025;
CD45RA/CD45RO: P 0.025; CD56: P 0.025; CD57: P 0.025; CD94: P 0.040; CD158a: P 0.05; CD161: P 0.05; HLA-DR: P 0.025; NKB1: P 0.05. No significant differences
were observed between AIM patients and controls as regards the overall percentage of CD2 (99  0 versus 99  1), CD5 (96  2 versus 86  7), and CD7 (99  1 versus 99  1) cells.
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shown in Tables 3 and 4. Normal PB TCR T-cells were
rather heterogeneous and a relatively large fraction of them
exhibited a cytotoxic-like immunophenotype, as defined by
the expression of NK-associated markers and killer recep-
tors (CD16, CD56, CD57, CD94, CD158a, CD161, NKB1)
(Table 4). In contrast, in those patients with AIM who
showed increased numbers of TCR T-cells the pheno-
type of these cells was quite homogeneous and, except for
the high levels of expression of CD94 and CD161, they
failed to express other NK-associated markers (Table 4).
Overall, in these 3 AIM patients, more than 90% of
TCR T-cells display an activation-associated pheno-
type: coexpression of HLA-DR and CD38, low levels of
CD5, CD7 and CD28 and high levels of CD2 and CD11a
(Table 3). Moreover, as noted for the CD8/TCR T-
cells, a variable fraction of TCR T-cells stained dimly
for CD11b and CD11c (Table 4). Differences between pa-
tients and controls were found to be statistically significant
only for a higher percentage of HLA-DR, CD38,
CD11ahigh, CD45RO and CD94 cells (P  0.04 for
CD94 and P  0.025 for the remaining markers) together
with a lower proportion of CD28; CD56, CD45RA,
CD45RA/CD45RO and CD57/TCR T-cells in
AIM patients (P  0.025 for all markers). Differences
concerning the intensity of expression of each of these
markers were found to be significant only for a few anti-
gens, consisting of a lower reactivity for CD28 (P  0.025)
and CD45RA (P 0.05) and higher expression of HLA-DR
(P  0.025), CD11a (P  0.05) and CD38 (P  0.05) on
TCR cells from AIM patients.
TCR-V, -V and -V repertoire of expanded PB T-cells
The study of the TCR-V T-cell repertoire revealed the
existence of small expansions of one or more TCR-V
families in 12 of 14 cases analysed (Table 5). From these
cases, 5 showed expansions among CD8/TCR, 2
among CD4/TCR and 5 in both T-cell subsets; over-
all, a total of 23 TCR-V expansions were detected, 13
corresponding to CD8 and 10 to CD4/TCR T-lym-
phocytes. In the majority of cases, the TCR-V expansions
detected were small, being slightly above the cutoff values
(mean  2 standard deviation) obtained in normal individ-
uals and in any case represented more than 30% of either the
CD8 or the CD4/TCR T-cell compartments (mean
of 12  7%; range: 3 to 30%). The largest TCR-V expan-
sions occurring in CD8/TCR T-cells (V2.1: 22%
and V17.1: 27%) were found in the two splenectomised
patients who also showed the highest percentage of CD8/
CD57 T-cells (65 and 26%, respectively) in the PB. As
shown in Table 5, TCR-V expansions were not restricted
to particular TCR-V families either within CD8 or
among CD4/TCR T-cells.
In those patients presenting with increased numbers of
TCR T-cells, the majority of TCR T-lymphocytes
co-expressed the TCR-V2 and the TCR-V9 families,
which represented 97% and 97% of TCR T-cells in case
1, 98% and 97% in case 2 and 80% and 80% in case 3,
respectively; such distribution mimics what is observed in
the PB of normal adult individuals (mean of 75  21% and
of 79 16%, for TCR-V2 and TCR-V9 families, respec-
tively).
Discussion
From the clinical point of view acute infectious mono-
nucleosis is a relatively heterogeneous syndrome due to an
underlying acute viral infection in accordance to what has
been found in the present series. From the immunological
point of view, acute viral infection has been reported to
induce a redistribution of PB lymphocytes characterized by
an increased of CD8 T-cells [25–27]. Interestingly, in the
present study we have shown the existence of marked phe-
notypic changes consistent with an extensive activation of
all the PB T-cell subsets, especially within the CD8/
TCR T-cell compartment. CD8/TCR T-cells
showed an intriguing stable immunophenotypic pattern—
CD2high, CD7dim, CD11ahigh, CD28/dim, CD38high,
CD45ROhigh, CD45RA/dim, HLA-DRhigh—which has
been associated with a state of recent T-cell activation
[45–57]. It should be noted that in agreement with previous
reports [61] there was a marked decrease in the expression
of p26/bcl2 on CD8 T-cells, indicating that activated
Table 5
TCR-V expansions within peripheral blood CD8/TCR and
CD4/TCR T-cell subsets in AIM patients
Case
number
% CD8/TCR T-cellsa % CD4/TCRT-cellsa
1 — TCR-V12.2: 12% (2%)
2 TCR-V2.1: 18% (8%) —
3 TCR-V2.1: 22% (8%) TCR-V2.1: 15% (11%)
TCR-V20.1: 5% (3%) TCR-V17.1:10% (7%)
4 TCR-V3.1: 14% (11%) TCR-V23.1: 3% (1%)
5 — TCR-V8.1  8.2: 7% (5%);
TCR-V22.1: 7% (5%)
6 — —
7 TCR-V12.2 17% (2%) —
8 TCR-V20.1: 6% (3%) —
9 — —
10 TCR-V3.1: 13% (11%) TCR-V8.1  8.2: 13%
(5%)
11 TCR-V8.1  8.2: 9%
(7%)
TCR-V8.1  8.2: 6% (5%)
TCR-V13.6: 7% (3%) TCR-V22.1: 7% (5%)
12 TCR-V17.1: 18% (10%) —
TCR-V18.1: 5% (1%)
13 TCR-V1: 11% (6%) N.D.
14 V17.1: 27% (10%) TCR-V13.6: 30% (2%)
Note. N.D., not determined.
a Results are expressed as the percentage of CD8 or CD4/TCR
T-cells that expressed the expanded TCR-V families (the specific normal
upper limit is shown in parentheses).
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CD8 T-cells are prone to apoptosis. TCR and CD4/
TCR T-cells also showed immunophenotypic evidence
of being activated, although to a lesser extent. In fact,
recently activated T-cells—defined as CD2high, CD7dim,
CD11ahigh, CD38 and HLA-DR—accounted for about
95% of the total PB CD8/TCR T-cells in this series of
AIM patients, whereas they only represented around half of
circulating CD4/TCR T-lymphocytes. In that con-
cerning the magnitude of TCR T-cell activation, al-
though our results indicate that more than 90% of TCR
T-cells displayed an activation-related immunophenotype in
all three cases in whom the phenotype of TCR T-cells
was completely characterized, results were probably biased
by the fact that those patients were selected because of
having the highest TCR T-cell counts. The fact that
increased numbers of TCR T-cells were observed in
only 46% of cases—compared to 61% and 96% for CD4
and CD8/TCR T-cells, respectively—would suggest
that T-cell response in AIM would mainly involve TCR
T-cells and is consistent with the existence of a predominant
MHC-restricted T-helper type 1 (Th1) mediated cytotoxic
response. Besides this extensive T-cell activation, AIM pa-
tients also showed evidence for NK-cell activation sug-
gested by both the increased numbers of total PB NK cells
and the fraction of activated (HLA-DR) NK-cells (data not
shown).
Except for differences observed in a few antigens, the
phenotypic features of activated CD4/TCR and
TCR were similar to that described for CD8/TCR
T-cells, but less pronounced. Specific differences consisted
of the following: (i) down-regulation of CD5 was not ob-
served and decreased expression of CD28 was much less
evident on CD4/TCR than on the CD8/TCR
and TCR T-cells; (ii) there was no evidence for down-
regulation of CD3 on activated TCR T-cells, levels of
CD3 being higher than those observed in normal TCR
T-cells; (iii) in contrast to what was observed for TCR
T-cells, that were either negative of expressed low levels of
CD94 and CD161, activated TCR T-cells displayed
high reactivity for these lectin-like killer receptors; (iv) ac-
tivated CD4/TCR T-cells did not express CD11c,
whereas this adhesion molecule was dimly expressed on a
variable fraction of CD8/TCR and TCR T-cells in
the majority of cases.
The majority of the alterations described here have al-
ready been recognized as occurring after T-cell activation
using in vitro or in vivo models, including up-regulation of
CD2, CD11a, CD11b and CD11c adhesion molecules,
CD38, CD45RO and HLA-DR together with down-regula-
tion of CD3, CD7, CD28 and CD45RA [45–57]. Reactivity
for CD25, which has also been described to increase after
T-cell activation both in vitro and in vivo, did not prove to
be a good indicator of T-cell activation in this model.
The immunophenotypic pattern described above identi-
fies an early/intermediate phase of T-cell activation. Late-
activation antigens, such as CD57, were only present in a
small proportion of CD8/TCR T-cells, the percentage
of CD8/CD57 exceeding 20% in only three cases. Inter-
estingly, two of these patients had been previously splenec-
tomised, supporting the hypothesis that the increased pro-
portion of CD8/CD57 T-cells could be more likely
related to splenectomy than to the acute viral infection itself
[62]. An alternative possibility would be that expression of
CD57 could represent a marker directly related to disease
outcome. In this sense, it should be noted that the only
patient that became chronically infected with CMV was the
one showing the highest proportion of CD8/CD57 cells.
CD8/CD57 T-cells were previously characterized as a
particular subtype of large granular lymphocytes with an
activated/memory T-cell phenotype that exhibit immuno-
regulatory suppressive functions and that are preferentially
increased in conditions characterized by chronic antigen
stimulation [58–60]. Several studies also provided evidence
for the existence of dynamic changes in the phenotype of
PB T-cells after viral infection; accordingly, it has been
shown that the majority of CD8/TCR T-cells ob-
served during the first weeks after primary CMV infection
are CD57 and that CD8/CD57 T-cells are progressively
replaced by CD8/CD57 T-cells in patients that become
chronically infected [59].
In order to gain further insights into the immune mech-
anisms involved in AIM, we have also analysed both the
TCR-V and the TCR-V/V repertoires in representative
subgroups of patients with AIM. Interestingly, whereas
TCR T-cells showed a TCR-V/V distribution similar
to that of normal TCR T-cells, small expansions of
specific TCR-V families were found in both the CD8 and
CD4/TCR T-cell compartments in the majority of
cases analysed, in agreement with previous observations
[41,43,44]. However, in contrast to some of these studies
[43] we did not find evidence for a selective expansion of
any of the TCR-V families. Even more, the type of
TCR-V family did not show any correlation with the
specific virus identified as responsible for AIM (data not
shown). The magnitude of the TCR-V expansion never
exceeded 40% of the CD8 or the CD4 T-cells, which
favours the hypothesis of a polyclonal/oligoclonal, rather
than monoclonal, T-cell proliferation [63] in accordance
with previous studies [42]. Interestingly, it should be noted
that the highest expansions of specific TCR-V families
occurred in those patients that showed the greatest levels of
expression of CD57. This observation would support pre-
vious reports in which it has been demonstrated that CD8/
CD57 T-cells have a restricted TCR-V repertoire [64].
Further re-evaluation of this group of patients with AIM at
different time periods after the acute episode could probably
shed some light on whether CD57 TCR-V restricted
T-cell expansions occurring in AIM are directly related to
the persistent stimulation of T-cells by either viral antigens
or superantigens.
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